Essais de polychimiothérapie de la lèpre au Sénégal: premières observations relatives à la tolérance hépatique des maladies multibacillaires--conséquences thérapeutiques.

Translated title of the contribution: Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences

J. Millan, G. Roux, S. Loko, J. C. Naudin, P. Boucher, M. Bodian, M. Camara, T. Moreira-Diop, J. Grosset

Research output: Contribution to journalArticle

Abstract

The authors have studied tolerance of multibacillary patients to 4 MDT regimens. These 4 regimens consist of: One supervised part in which RMP-ETH combination in once-monthly administered; furthermore, in 2 of these regimens, is included one "starter phase" with daily doses of that combination for 2 months. One self-administered part during which CLO is associated either to DDS for new cases, or to ETH for relapses. Clinical Supervision: Out to 310 multibacillary patients, 7 cases of hepatitis with or without icterus, but no death due to the treatment. Interruptions of MDT have been temporary and have been observed in 0.9 to 5.6% of the patients according to the therapeutic regimen. Checking SGOT: The SGOT were abnormally high in 16.3% of the patients before treatment. These pre-existing liver damages do not favour the appearance of intolerance disorders. During MDT, abnormal increases in SGOT are observed in 27% of the patients but there is no exact correlation between the absorbed doses of ETH and the frequency in SGOT increases. The clinical or biological evidence of liver damages occur rather early (1st, 2nd month) in regimens with "starter phase", and later (4th-8th month) in those without "starter phase". But introduction of "Starter phase" does not increase the global frequency of such intolerance accidents. ETH combined with RMP, must be used under steady clinical and biological supervision. Recalling the results of a previous survey, the authors consider that a long duration of MDT is not necessary. For the multibacillary leprosy treatment, they propose a diphasic regimen, more easily applicable in the field than the WHO protocols. In this diphasic regimen, the only part which must be supervised is the initial "starter phase" of 2 month. It consists of daily administration of 3 antibacillary drug among which RMP and ETH. The second phase is a relay treatment using 2 drugs, CLO combined with DDS or ETH, self-administered until smear negativity.

Original languageFrench
Pages (from-to)427-444
Number of pages18
JournalActa Leprologica
Volume4
Issue number4
StatePublished - Oct 1986
Externally publishedYes

Fingerprint

Senegal
Leprosy
Aspartate Aminotransferases
Drug Therapy
Liver
Multibacillary Leprosy
Therapeutics
Jaundice
Pharmaceutical Preparations
Hepatitis
Accidents
Recurrence

ASJC Scopus subject areas

  • Dermatology

Cite this

Essais de polychimiothérapie de la lèpre au Sénégal : premières observations relatives à la tolérance hépatique des maladies multibacillaires--conséquences thérapeutiques. / Millan, J.; Roux, G.; Loko, S.; Naudin, J. C.; Boucher, P.; Bodian, M.; Camara, M.; Moreira-Diop, T.; Grosset, J.

In: Acta Leprologica, Vol. 4, No. 4, 10.1986, p. 427-444.

Research output: Contribution to journalArticle

Millan, J, Roux, G, Loko, S, Naudin, JC, Boucher, P, Bodian, M, Camara, M, Moreira-Diop, T & Grosset, J 1986, 'Essais de polychimiothérapie de la lèpre au Sénégal: premières observations relatives à la tolérance hépatique des maladies multibacillaires--conséquences thérapeutiques.', Acta Leprologica, vol. 4, no. 4, pp. 427-444.
Millan, J. ; Roux, G. ; Loko, S. ; Naudin, J. C. ; Boucher, P. ; Bodian, M. ; Camara, M. ; Moreira-Diop, T. ; Grosset, J. / Essais de polychimiothérapie de la lèpre au Sénégal : premières observations relatives à la tolérance hépatique des maladies multibacillaires--conséquences thérapeutiques. In: Acta Leprologica. 1986 ; Vol. 4, No. 4. pp. 427-444.
@article{2bd3d469dc4b4850a9d0cfe3be59b75c,
title = "Essais de polychimioth{\'e}rapie de la l{\`e}pre au S{\'e}n{\'e}gal: premi{\`e}res observations relatives {\`a} la tol{\'e}rance h{\'e}patique des maladies multibacillaires--cons{\'e}quences th{\'e}rapeutiques.",
abstract = "The authors have studied tolerance of multibacillary patients to 4 MDT regimens. These 4 regimens consist of: One supervised part in which RMP-ETH combination in once-monthly administered; furthermore, in 2 of these regimens, is included one {"}starter phase{"} with daily doses of that combination for 2 months. One self-administered part during which CLO is associated either to DDS for new cases, or to ETH for relapses. Clinical Supervision: Out to 310 multibacillary patients, 7 cases of hepatitis with or without icterus, but no death due to the treatment. Interruptions of MDT have been temporary and have been observed in 0.9 to 5.6{\%} of the patients according to the therapeutic regimen. Checking SGOT: The SGOT were abnormally high in 16.3{\%} of the patients before treatment. These pre-existing liver damages do not favour the appearance of intolerance disorders. During MDT, abnormal increases in SGOT are observed in 27{\%} of the patients but there is no exact correlation between the absorbed doses of ETH and the frequency in SGOT increases. The clinical or biological evidence of liver damages occur rather early (1st, 2nd month) in regimens with {"}starter phase{"}, and later (4th-8th month) in those without {"}starter phase{"}. But introduction of {"}Starter phase{"} does not increase the global frequency of such intolerance accidents. ETH combined with RMP, must be used under steady clinical and biological supervision. Recalling the results of a previous survey, the authors consider that a long duration of MDT is not necessary. For the multibacillary leprosy treatment, they propose a diphasic regimen, more easily applicable in the field than the WHO protocols. In this diphasic regimen, the only part which must be supervised is the initial {"}starter phase{"} of 2 month. It consists of daily administration of 3 antibacillary drug among which RMP and ETH. The second phase is a relay treatment using 2 drugs, CLO combined with DDS or ETH, self-administered until smear negativity.",
author = "J. Millan and G. Roux and S. Loko and Naudin, {J. C.} and P. Boucher and M. Bodian and M. Camara and T. Moreira-Diop and J. Grosset",
year = "1986",
month = "10",
language = "French",
volume = "4",
pages = "427--444",
journal = "Acta Leprologica",
issn = "0001-5938",
publisher = "Ordre de Malte Pour I'Assistance aux Lepreux",
number = "4",

}

TY - JOUR

T1 - Essais de polychimiothérapie de la lèpre au Sénégal

T2 - premières observations relatives à la tolérance hépatique des maladies multibacillaires--conséquences thérapeutiques.

AU - Millan, J.

AU - Roux, G.

AU - Loko, S.

AU - Naudin, J. C.

AU - Boucher, P.

AU - Bodian, M.

AU - Camara, M.

AU - Moreira-Diop, T.

AU - Grosset, J.

PY - 1986/10

Y1 - 1986/10

N2 - The authors have studied tolerance of multibacillary patients to 4 MDT regimens. These 4 regimens consist of: One supervised part in which RMP-ETH combination in once-monthly administered; furthermore, in 2 of these regimens, is included one "starter phase" with daily doses of that combination for 2 months. One self-administered part during which CLO is associated either to DDS for new cases, or to ETH for relapses. Clinical Supervision: Out to 310 multibacillary patients, 7 cases of hepatitis with or without icterus, but no death due to the treatment. Interruptions of MDT have been temporary and have been observed in 0.9 to 5.6% of the patients according to the therapeutic regimen. Checking SGOT: The SGOT were abnormally high in 16.3% of the patients before treatment. These pre-existing liver damages do not favour the appearance of intolerance disorders. During MDT, abnormal increases in SGOT are observed in 27% of the patients but there is no exact correlation between the absorbed doses of ETH and the frequency in SGOT increases. The clinical or biological evidence of liver damages occur rather early (1st, 2nd month) in regimens with "starter phase", and later (4th-8th month) in those without "starter phase". But introduction of "Starter phase" does not increase the global frequency of such intolerance accidents. ETH combined with RMP, must be used under steady clinical and biological supervision. Recalling the results of a previous survey, the authors consider that a long duration of MDT is not necessary. For the multibacillary leprosy treatment, they propose a diphasic regimen, more easily applicable in the field than the WHO protocols. In this diphasic regimen, the only part which must be supervised is the initial "starter phase" of 2 month. It consists of daily administration of 3 antibacillary drug among which RMP and ETH. The second phase is a relay treatment using 2 drugs, CLO combined with DDS or ETH, self-administered until smear negativity.

AB - The authors have studied tolerance of multibacillary patients to 4 MDT regimens. These 4 regimens consist of: One supervised part in which RMP-ETH combination in once-monthly administered; furthermore, in 2 of these regimens, is included one "starter phase" with daily doses of that combination for 2 months. One self-administered part during which CLO is associated either to DDS for new cases, or to ETH for relapses. Clinical Supervision: Out to 310 multibacillary patients, 7 cases of hepatitis with or without icterus, but no death due to the treatment. Interruptions of MDT have been temporary and have been observed in 0.9 to 5.6% of the patients according to the therapeutic regimen. Checking SGOT: The SGOT were abnormally high in 16.3% of the patients before treatment. These pre-existing liver damages do not favour the appearance of intolerance disorders. During MDT, abnormal increases in SGOT are observed in 27% of the patients but there is no exact correlation between the absorbed doses of ETH and the frequency in SGOT increases. The clinical or biological evidence of liver damages occur rather early (1st, 2nd month) in regimens with "starter phase", and later (4th-8th month) in those without "starter phase". But introduction of "Starter phase" does not increase the global frequency of such intolerance accidents. ETH combined with RMP, must be used under steady clinical and biological supervision. Recalling the results of a previous survey, the authors consider that a long duration of MDT is not necessary. For the multibacillary leprosy treatment, they propose a diphasic regimen, more easily applicable in the field than the WHO protocols. In this diphasic regimen, the only part which must be supervised is the initial "starter phase" of 2 month. It consists of daily administration of 3 antibacillary drug among which RMP and ETH. The second phase is a relay treatment using 2 drugs, CLO combined with DDS or ETH, self-administered until smear negativity.

UR - http://www.scopus.com/inward/record.url?scp=0022788788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022788788&partnerID=8YFLogxK

M3 - Article

C2 - 3296613

AN - SCOPUS:0022788788

VL - 4

SP - 427

EP - 444

JO - Acta Leprologica

JF - Acta Leprologica

SN - 0001-5938

IS - 4

ER -